As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance
Blockbuster Potential In Late-Stage Pipeline
Executive Summary
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.